Deniz Türkmen

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 13

Top Topics

Low Density Lipoprotein

Cardiovascular Risk Factors

Angiotensin Converting Enzyme

Top Venues

The pharmacogenomics journal

International journal of molecular sciences

British journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Deniz Türkmen, Jack Bowden, Jane A H Masoli, João Delgado, Chia-Ling Kuo, David Melzer, Luke C Pilling
Polygenic scores for cardiovascular risk factors improve estimation of clinical outcomes in CCB treatment compared to pharmacogenetic variants alone. The pharmacogenomics journal 24 (3) (2024)
Deniz Türkmen, Jack Bowden, Jane A H Masoli, David Melzer, Luke C Pilling
SLCO1B1 Exome Sequencing and Statin Treatment Response in 64,000 UK Biobank Patients. International journal of molecular sciences 25 (8) (2024)
Deniz Türkmen, Jack Bowden, Jane A H Masoli, David Melzer, Luke C Pilling
SLCO1B1 Exome Sequencing and Statin Treatment Response in 64,000 UK Biobank Patients. International journal of molecular sciences 25 (8) (2024)
Deniz Türkmen, Jack Bowden, Jane A H Masoli, João Delgado, Chia-Ling Kuo, David Melzer, Luke C Pilling
Polygenic scores for cardiovascular risk factors improve estimation of clinical outcomes in CCB treatment compared to pharmacogenetic variants alone. The pharmacogenomics journal 24 (3) (2024)
Deniz Türkmen, Jack Bowden, Jane A H Masoli, João Delgado, Chia-Ling Kuo, David Melzer, Luke C Pilling
Polygenic scores for cardiovascular risk factors improve estimation of clinical outcomes in CCB treatment compared to pharmacogenetic variants alone. The pharmacogenomics journal 24 (3) (2024)
Deniz Türkmen, Jack Bowden, Jane A H Masoli, João Delgado, Chia-Ling Kuo, David Melzer, Luke C Pilling
Polygenic scores for cardiovascular risk factors improve estimation of clinical outcomes in CCB treatment compared to pharmacogenetic variants alone. The pharmacogenomics journal 24 (3) (2024)
Deniz Türkmen, Jack Bowden, Jane A H Masoli, João Delgado, Chia-Ling Kuo, David Melzer, Luke C Pilling
Polygenic scores for cardiovascular risk factors improve estimation of clinical outcomes in CCB treatment compared to pharmacogenetic variants alone. The pharmacogenomics journal 24 (3) (2024)
Deniz Türkmen, Jack Bowden, Jane A H Masoli, David Melzer, Luke C Pilling
SLCO1B1 Exome Sequencing and Statin Treatment Response in 64,000 UK Biobank Patients. International journal of molecular sciences 25 (8) (2024)
Deniz Türkmen, Jack Bowden, Jane A H Masoli, João Delgado, Chia-Ling Kuo, David Melzer, Luke C Pilling
Polygenic scores for cardiovascular risk factors improve estimation of clinical outcomes in CCB treatment compared to pharmacogenetic variants alone. The pharmacogenomics journal 24 (3) (2024)
Deniz Türkmen, Jane A H Masoli, Chia-Ling Kuo, Jack Bowden, David Melzer, Luke C Pilling
Statin treatment effectiveness and the SLCO1B1*5 reduced function genotype: Long-term outcomes in women and men. British journal of clinical pharmacology 88 (7) (2022)
Deniz Türkmen, Jane A H Masoli, João Delgado, Chia-Ling Kuo, Jack Bowden, David Melzer, Luke C Pilling
Calcium-channel blockers: Clinical outcome associations with reported pharmacogenetics variants in 32 000 patients. British journal of clinical pharmacology (2022)
Jack Bowden, Luke C Pilling, Deniz Türkmen, Chia-Ling Kuo, David Melzer
The Triangulation WIthin a STudy (TWIST) framework for causal inference within pharmacogenetic research. PLoS genetics 17 (9) (2021)
Luke C Pilling, Deniz Türkmen, Hannah Fullalove, Janice C Atkins, João C Delgado, Chia-Ling Kuo, George A Kuchel, Luigi Ferrucci, Jack Bowden, Jane A H Masoli, David Melzer
Analysis of CYP2C19 genetic variants with ischaemic events in UK patients prescribed clopidogrel in primary care: a retrospective cohort study. BMJ open 11 (12) (2021)